52nd week of 2018 patent applcation highlights part 9 |
Patent application number | Title | Published |
20180369105 | USE OF DIHYDROISOQUINOLINIUM DOUBLE DERIVATIVES FOR TREATING KERATIN MATERIALS, COMPOSITIONS AND IMPLEMENTATION PROCESSES - The present invention relates to the use of one or more dihydroisoquinolinium double salts for treating keratin materials, in particular keratin fibres, especially human keratin fibres such as the hair. The invention also relates to a process for treating keratin materials using said salts and optionally in the presence of one or more chemical oxidizing agents. A subject of the invention is also a composition for lightening keratin materials, comprising one or more dihydroisoquinolinium double salts as defined below and one or more chemical oxidizing agents. The present invention also relates to one or more particular dihydroisoquinolinium double salts and also to compositions containing them, in particular compositions comprising a physiologically acceptable medium. | 2018-12-27 |
20180369106 | COMBINATION OF POLYION COMPLEX PARTICLE AND HYDROPHILIC OR WATER-SOLUBLE UV FILTER - The present invention relates to a composition according to the present invention comprises: (a) at least one particle comprising at least one cationic polymer, at least one anionic polymer, and at least one hydrophilic or water-soluble UV filter; and (b) at least one physiologically acceptable volatile medium. The composition according to the present invention is stable, and can have a variety of cosmetic functions. For example, the composition according to the present invention can prepare a film which can have cosmetic effects such as UV filtering, as well as absorbing or adsorbing malodor, changing the appearance of a keratin substrate such as skin, changing the feel to the touch of the keratin substrate, and/or protecting the keratin substrate from, for example, dirt or pollutants. | 2018-12-27 |
20180369107 | PROCESS FOR TREATING KERATIN FIBRES USING AN AQUEOUS COMPOSITION COMPRISING A COMBINATION OF PARTICULAR ALKOXYSILANES - The invention relates to a process for treating keratin fibres, which comprises the application of a composition comprising: (a) one or more alkoxysilanes comprising solubilizing function(s) of formula R | 2018-12-27 |
20180369108 | COMPOSITION COMPRISING A COMBINATION OF PARTICULAR ALKOXYSILANES AND A FATTY SUBSTANCE - The invention relates to a composition comprising: (a) one or more alkoxysilanes bearing solubilizing function(s) of formula R | 2018-12-27 |
20180369109 | COMPOSITION COMPRISING THE COMBINATION OF SPECIFIC ALKOXYSILANES AND OF A SURFACTANT - The invention relates to a composition comprising: (a) one or more alkoxysilanes comprising solubilizing function(s) of formula R | 2018-12-27 |
20180369110 | Composition and Method for Improving the Appearance of Skin - Low pH cosmetic compositions and methods for improving the appearance of skin. The low pH cosmetic compositions herein include a saccharide and, optionally, one or more additional skin care actives to improve the appearance of skin. The lower pH reduces or even eliminates some of the skin health and appearance drawbacks associated with saccharide induced glycation. | 2018-12-27 |
20180369111 | COMPOSITION COMPRISING BAICALIN AT A HIGH CONCENTRATION - Composition comprising baicalin at a high concentration The invention relates to a composition comprising at least one aqueous phase comprising baicalin, or an extract containing same, baicalin being solubilized and present at a mass concentration comprised between 0.25% and 10% with respect to the total mass of the composition, said composition having a p H of 5 to 6 and said composition being an emulsion. The invention also relates to a method for preparing such a composition and the uses of such a composition, particularly in cosmetics. | 2018-12-27 |
20180369112 | CATIONIC AND NONIONIC SURFACTANT CLEANSING COMPOSITION - An aqueous cleansing composition comprising a cationic surfactant, a nonionic surfactant, and a thickener comprising an alkoxylated methyl glucose ether, wherein a weight ratio of cationic surfactant to nonionic surfactant is greater than 0.9:1. The combination of the cationionic:nonionic surfactant ratio with the alkoxylated methyl glucose ether thickener provides the composition with cold weather stability. Cold weather stability is observed when the composition remains transparent after cold storage. | 2018-12-27 |
20180369113 | PERSONAL CARE FORMULATIONS COMPRISING CARMIN PROTEIN - Personal care products comprising a carmin protein are provided. The carmin protein may be obtained in a plant extract obtainable from plants belonging to the genus | 2018-12-27 |
20180369114 | COMPOSITION FOR SKIN WHITENING COMRPISING TNFSF14 PROTEIN - The present specification is intended to develop a new substance which exhibits a skin whitening effect and to apply the new substance to a composition for skin whitening, provides a new composition for skin whitening and a new kit for skin whitening which contain TNFSF14 protein and a polynucleotide encoding the TNFSF14 protein and a method of using the same, and thus can contribute to the market expansion and industry development related to the skin whitening field. | 2018-12-27 |
20180369115 | COMPOUNDS USEFUL IN THE TREATMENT AND/OR CARE OF THE SKIN, HAIR, NAILS, AND/OR MUCOUS MEMBRANES - Compounds of general formula (I): R1-Wm-Xn-AA1-AA2-AA3-AA4-AA5-AA6-Yp-Zq-R2 (I) their stereoisomers, mixtures thereof and/or their cosmetically or pharmaceutically acceptable salts, cosmetic and/or pharmaceutical compositions which contain them and their use in medicine, and in processes of treatment and/or care of the skin, hair and/or mucous membranes, in particular in the aging and photoaging of the skin. | 2018-12-27 |
20180369116 | PREPARATIONS COMPRISING CARNOSINES - The invention relates to a preparation containing at least one compound of formula (I), providing that R1 is H or CH | 2018-12-27 |
20180369117 | COSMETIC COMPOSITIONS AND METHODS OF USE - Keratin protein cosmetic compositions are provided that include at least one keratin protein derived from human hair and a base cosmetic solution. Methods of treatment are also provided. | 2018-12-27 |
20180369118 | METHODS FOR SPORE REMOVAL - Disclosed herein are methods for removing spores from skin, the method including dispensing an effective amount of a composition into or onto an article, wherein the composition includes water and from 0.15 wt % to 4 wt % anionic thickener; contacting a skin surface with the composition; mechanically acting on the skin surface for at least one (1) second while the skin surface is in the presence of the composition; and removing at least a portion of the composition from the surface of the skin, wherein removing the composition also removes spores from the skin surface. | 2018-12-27 |
20180369119 | High Shine, Long Wear Color Cosmetic Compositions - High shine single phase color cosmetic compositions that are flexible and resistant to water below a selected temperature, 43° C. for example. The compositions wear well, are smudge and flake resistant, as well as oil resistant, making them very suitable as high shine, long wear cosmetics. Compositions according to the invention comprise specific combinations of acrylates/VA copolymer and acrylates copolymer in a cosmetically acceptable base or delivery vehicle. Compositions according to the invention are hydrophilic and easily removed when scrubbed with water above a certain temperature, but not as easily removed with water below that temperature. The compositions are easy to manufacture, flexible and comfortable, and suitable for use on skin, hair and nails, particularly as eye shadow, eyeliner, lip products, tattoo products and mascara. Compositions may be formulated as liquid eyeliner, liquid eye shadow, mascara, liquid lip products and tattoo products. | 2018-12-27 |
20180369120 | FRAGRANCE DELIVERY COMPOSITION COMPRISING COPOLYMERS OF ACRYLOYL LACTAM AND ALKYLMETHACRYLATES, PROCESS FOR PREPARING THE SAME, AND METHOD OF USE THEREOF - Disclosed herein is an oil soluble composition comprising a copolymer having repeating units of: (i) about 0.1-99.9 wt. % of at least one monomer selected from at least one hydrophobically modified (alk) acrylate moiety; and (ii) about 0.1-99.9 wt. % of at least one monomer derived from at least one functionalized or unfunctionalized acryloyl moiety and at least one lactam moiety. Also, disclosed herein is a mineral oil soluble personal care and fragrance composition comprising such copolymer, a fragrance delivery system and method of delivering fragrance. | 2018-12-27 |
20180369121 | Cosmetic Adhesive Compositions - Single phase cosmetic adhesive compositions that are flexible and resistant to water below a selected temperature, 43° C. for example. The adhesive compositions wear well, are smudge and flake resistant, as well as oil resistant, making them very suitable for long wear without adhesive failure. Adhesive compositions according to the invention comprise specific combinations of acrylates/VA copolymer and acrylates copolymer in a cosmetically acceptable base or delivery vehicle. Adhesive compositions according to the invention are hydrophilic and easily removed when scrubbed with water above a certain temperature, but not as easily removed with water below that temperature. The adhesive compositions are easy to manufacture, flexible and comfortable, and suitable for use on skin, lips, hair and nails, particularly to secure strips of false eyelashes and eyebrows, as well as individual lash and brow extensions. Cosmetic adhesives of the present invention may also be used to affix glitter or extensions to skin, hair, lips, or nails, and other cosmetic products to keratinic surfaces. | 2018-12-27 |
20180369122 | Oral Care Compositions Comprising At Least One Phosphate/Acrylate Copolymer And At Least One Cationic Active Ingredient - Disclosed herein are oral care compositions comprising at least one phosphate/acrylate copolymer, at least one cationic antibacterial agent, at least one synthetic anionic linear polycarboxylate polymer, at least one surfactant, and zinc lactate. Also disclosed herein are methods for the treatment and/or inhibition of gum disease or halitosis comprising contacting the oral cavity with the oral care compositions disclosed herein, as well as methods of making the oral care compositions disclose herein. | 2018-12-27 |
20180369123 | COSMETIC PROCESS FOR TREATING KERATIN MATERIALS WITH A MALEIC ANHYDRIDE ETHYLENIC POLYMER - The invention relates to a cosmetic process for treating keratin materials, comprising: either the sequential application to the keratin materials of a composition comprising a maleic anhydride ethylenic polymer and of an amine compound chosen from polyamine compounds bearing several primary amine and/or secondary amine groups and amino alkoxysilanes, or the topical application to the keratin materials of a composition derived from the mixing of a composition comprising a maleic anhydride acrylic polymer and of an amine compound chosen from amino alkoxysilanes; the ethylenic polymer being derived from the polymerization of: (a) 45% to 95% by weight, relative to the total weight of monomers, of an ethylenic monomer bearing an at least C8 linear or branched alkyl group; (b) 5% to 25% by weight of maleic anhydride; (c) 0 to 50% by weight of additional monomer; the compositions used being anhydrous when the amine compound is an amino alkoxysilane. The process makes it possible to obtain a film-forming deposit that has good resistance to water, to oil and to sebum. The film is also non-tacky and transfer-resistant. | 2018-12-27 |
20180369124 | HAIR TREATMENT PROCESS - The present invention relates to a hair treatment process wherein an aqueous composition comprising one or more cationic polymers having certain cationic change density is applied onto hair and without rinsing off the temperature of the hair is increased. The novel treatment process allows consumers to a long lasting conditioning of their hair. | 2018-12-27 |
20180369125 | PROCESS FOR TREATING HAIR USING AQUEOUS DISPERSIONS OF PARTICULAR POLYMERS AND HEAT - The present invention relates to a process for treating the hair, which comprises: a) applying to hair a composition comprising at least one aqueous dispersion of silicone particles and polyurethane particles, then or simultaneously, b) heating the hair to a temperature comprised inclusively between 50° C. and 250° C. using a heating device. | 2018-12-27 |
20180369126 | OILY SOLID COSMETIC - An oily solid cosmetic contains an alkyl-polyether-modified silicone having a siloxane dendron structure and a dimer acid ester. The oily solid cosmetic may also contain a candelilla wax resin and a low viscosity oil having a viscosity of 5 to 100 mPa·s at 25° C. Example uses of the oily solid cosmetic include makeup cosmetics such as a lipstick, foundation, rouge, concealer, eye shadow, eyeliner, eyebrow, mascara, makeup base, and hair colorant. Additional uses include skin care cosmetics such as lip cream, lip balm, eye cream, moisturizing cream, and sunscreen. | 2018-12-27 |
20180369127 | COSMETIC PROCESS FOR TREATING KERATIN MATERIALS - The invention relates to a cosmetic process for caring for or making up keratin materials, comprising the sequential application to the keratin materials of a cosmetic composition comprising a maleic anhydride block polymer and a polyamine compound, said block polymer comprising: a first block with a glass transition temperature (Tg) of greater than or equal to 40° C. and is derived from a monomer CH | 2018-12-27 |
20180369128 | BLOCK POLYMER BEARING PHOSPHONIC ACID GROUPS AND COSMETIC USES THEREOF - The invention relates to a block polymer comprising: a first block with a glass transition temperature (Tg) of greater than or equal to 40° C., obtained from a monomer CH | 2018-12-27 |
20180369129 | MICROBIOME-COMPATIBLE COSMETICS - The systems and methods of the disclosure provide, inter alia, cosmetic products, e.g., finished cosmetic products that may be considered to be “biome-friendly” or “biome-compatible.” The systems and methods of the disclosure may provide for use of cosmetic products, e.g., finished cosmetic products, that may be used in combination with bacteria, e.g., non-pathogenic bacteria, e.g., ammonia oxidizing bacteria, which may be used in the form of a preparation or composition to be applied to a subject. | 2018-12-27 |
20180369130 | METHOD FOR REDUCING SKIN SAGGING AND/OR IMPROVING SKIN BRIGHTNESS BY USING GUM TRAGACANTH COMPOSITION - A method for reducing skin sagging and/or improving skin brightness is provided. The method comprises administering to a subject in need an effective amount of gum tragacanth composition, wherein the gum tragacanth composition comprises gum tragacanth and a pharmaceutically acceptable carrier and is topically administered to the skin at least once a day to achieve the effects of maintaining skin tightness and moisture and improving skin brightness. | 2018-12-27 |
20180369131 | Chemo-Enzymatic Site-Specific Modification of Peptides and Proteins to Form Cleavable Conjugates - A method is provided for reversibly modifying a protein or peptide on its glutamine residue(s) by performing a reaction, such as a transglutaminase-catalyzed reaction, between the protein or peptide and an amine-containing reagent, whereby the reagent is linked through its amine function to a side chain of the glutamine residue. Subjecting the modified protein to an appropriate stimulus regenerates the protein or peptide in its original form. | 2018-12-27 |
20180369132 | THERAPEUTIC AGENT TARGETING AND FIXATION MEDICAL DEVICE USING MAGNET ARRAY - Provided is a therapeutic agent targeting and fixation medical device that precisely targets a therapeutic agent including a magnetic substance by using an optimized array of magnets in consideration of an affected area of a patient. | 2018-12-27 |
20180369133 | AMPK AGONIST TOPICAL MEDICATION FOR THE TREATMENT OF CERTAIN SPECIFIC MEDICAL CONDITIONS, METHODS OF USE THEREOF AND WOUND DRESSING EMPLOYING THE SAME - A topical medication including a therapeutically effective amount of an AMPK (adenosine monophosphate-activated protein kinase) agonist for use in the treatment of one or more the human or animal medical conditions. The medical conditions include, but are not limited to: shingles (herpes zoster), post-herpetic neuralgia (PHN), gout, migraine, trigeminal neuralgia, Complex Regional Pain Syndrome (CRPS), diabetic neuropathy, peripheral neuropathy, rheumatoid arthritis, insect-related wheals, urushiol-related rash, psoriasis, herpes simplex, atopic dermatitis (eczema), contact dermatitis, allergic dermatitis, neurotrophic ulcers, first- and second-degree burns (e.g., sunburn and chemical), fibromyalgia, rubeola, and acne. Also disclosed are a method of employing the composition and a wound dressing incorporating a therapeutically effective amount of an AMPK agonist in combination with an antimicrobial agent. | 2018-12-27 |
20180369134 | Compositions and Methods of Transdermal Delivery for Therapeutic Agents - The present invention is a composition for transdermal delivery of a therapeutic agent and methods of treating a medical condition utilizing the composition. The composition comprises a natural oil, or first oil, of about 40% to about 75% w/w of the composition and contains about 3% to 11% behenic acid, a second oil of about 2% to about 15% w/w of the composition and contains oleic and/or palmitic acids selected from the group consisting of Tamanu oil, Argan oil, Shea butter, Pecan oil, canola oil, olive oil, poppy seed oil, sesame oil, sea buckthorn oil, grape seed oil, sunflower oil, | 2018-12-27 |
20180369135 | FORMULATIONS FOR INTRAVENOUS ADMINISTRATION - The present invention relates to an improved formulation of danirixin in its hydrobromide salt form. This improved formulation can be an aqueous intravenous formulation containing danirixin or a lyophilized pharmaceutical solid composition containing danirixin to be reconstituted to provide a solution for intravenous administration. | 2018-12-27 |
20180369136 | DEVICES AND METHODS FOR TRANSDERMAL TREATMENT OF BASAL CELL CARCINOMA - Various implementations include a transdermal drug delivery system for treating basal cell carcinoma. The system includes a pharmacologic agent and an array of microneedles for creating pores in the skin surface and the stratum corneum layer of the epidermis, thereby enabling transdermal delivery of the pharmacologic agent. The pharmacologic agent includes itraconazole and/or vitamin D3. Various implementations also include a method of treating basal cell carcinoma in a subject. The method includes: (1) applying an array of microneedles to a skin site having basal cell carcinoma, such that the microneedles penetrate the surface of the skin and the stratum corneum layer of the skin; and (2) administering a pharmaceutical composition to the subject intradermally through openings in the skin formed by the microneedles, wherein the pharmaceutical composition comprises a therapeutically effective amount of a pharmacologic chosen from itraconazole, vitamin D3, or a combination thereof. | 2018-12-27 |
20180369137 | Natural Lubricant - Personal lubricant compositions comprise: water, | 2018-12-27 |
20180369138 | GASTRIC RETENTIVE DEVICES - Provided are devices that are configured for gastric retention for a period of at least six hours (or at least three hours if the subject is in the fasted state) while maintaining their structural integrity and releasing or holding an active or diagnostic agent into or in gastric fluid of a human subject over that period, as well as methods of delivering an agent over an extended period by orally administering such devices to a subject, uses of an enteric polymer in the formation of devices that deliver an agent over an extended period of time, and methods of making such devices. | 2018-12-27 |
20180369139 | LIQUID INHALATION FORMULATION COMPRISING RPL554 - The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one (RPL554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment of the human or animal body. | 2018-12-27 |
20180369140 | NANOVECTORS FOR PENETRATING BRAIN TUMOR TISSUES TO CONDUCT GENE THERAPY - A method of selectively targeting a cell with a therapeutic agent, the method comprising: targeting a cell with a nanospear, puncturing the cell with said nanospear; releasing a therapeutic agent from said nanospear, wherein said therapeutic agent enters said cell, thereby effecting the efficacy of said cell. | 2018-12-27 |
20180369141 | MELFLUFEN DOSAGE REGIMENS FOR CANCER - The present invention providesmelflufen (melphalan flufenamide; L-Melphalanyl-4-fluoro-L-phenylalanine ethyl ester), or a salt thereof, for use in the treatment or prophylaxis of multiple myeloma, wherein a dosage of melflufen (excluding the mass of any salt) is administered as a parenteral dosage at an infusion rate of 1.0 to 1.8 mg/min. Also provided is melflufen, or a salt thereof, for use in the treatment or prophylaxis of a cancer, for example a solid cancer, wherein a dosage of melflufen is administered as a parenteral dosage at an infusion rate less than 0.8 mg/min (for example 0.3 to 1.0 mg/minor for example 0.3 to 0.8 mg/min). | 2018-12-27 |
20180369142 | AMPHIPHILIC POLYMER MICELLES AND USES THEREOF - By adjusting the spacing and length of particle surface moieties on amphiphilic micelles, hybridization kinetics, nuclease resistance, cellular uptake, and antisense efficacy of amphiphilic micelles are fine tuned. | 2018-12-27 |
20180369143 | METAL COMPLEXED THERAPEUTIC AGENTS AND LIPID-BASED NANOPARTICULATE FORMULATIONS THEREOF - A pharmaceutical formulation for delivery of a therapeutic agent having a metal complexation moiety and a solubility in water or a metal ion solution of less than 1 mg/ml. The formulation includes the therapeutic agent and a metal ion complexed inside a lipid-based nanoparticle formulation. | 2018-12-27 |
20180369144 | LIPID FORMULATIONS FOR DELIVERY OF MESSENGER RNA - The present invention provides, among other things, methods of delivering mRNA in vivo, including administering to a subject in need of delivery a composition comprising an mRNA encoding a protein, encapsulated within a liposome such that the administering of the composition results in the expression of the protein encoded by the mRNA in vivo, wherein the liposome comprises a cationic lipid of formula I-c: | 2018-12-27 |
20180369145 | Methods for the preparation of biologically active compounds in nanoparticulate form - A method for producing a composition comprising nanoparticles of a biologically active compound. | 2018-12-27 |
20180369146 | METHOD TO PRODUCE A MEDICINAL PRODUCT COMPRISING A BIOLOGICALLY ACTIVE PROTEIN AND THE RESULTING PRODUCT - The present invention pertains to a method for producing a medicinal product comprising a biologically active protein comprising the steps of providing an aqueous composition comprising a solvent, the biologically active protein and between 20% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, thereby forming at least one frozen body comprising the solvent in frozen form, putting the frozen body in a drying apparatus while being carried by a support, the support comprising one or more restraining elements that define one or more boundaries of the support, wherein at most 30% of the surface of the body is contiguous with the one or more restraining elements, reducing the pressure in the drying apparatus below atmospheric pressure, providing heat to the body in order to sublimate the frozen solvent of the body and obtain a dried body. The invention also pertains to a product obtainable by this method. | 2018-12-27 |
20180369147 | METHOD OF LYOPHILIZATION OF A SAMPLE OF FAECAL MICROBIOTA - Method for lyophilisation of a simple of fecal microbiota. The present invention relates to a method for lyophilisation of a sample of fecal microbiota from a donor subject, comprising the following steps: A) mixing of a sample of fecal microbiota from a donor subject with a diluent selected from polyols, disaccharides to pentasaccharides, maltodextrins and mixtures thereof, and B) freezing the mixture obtained in A) at a temperature of less than −50° C., preferably of between −70° C. and −100° C., followed by the lyophilisation thereof. | 2018-12-27 |
20180369149 | Tamper-resistant tablet providing immediate drug release - The invention relates to a tamper-resistant tablet comprising
| 2018-12-27 |
20180369151 | MULTIPARTICULATE ORAL DOSAGE FORM PROVIDING PROLONGED RELEASE OF TAPENTADOL - The invention relates to an oral pharmaceutical dosage form comprising a plurality of coated particles, wherein said coated particles comprise a core which comprises a Tapentadol component and which is coated with a controlled release coating material, wherein the controlled release coating material comprises a lubricant component and a polymer component, wherein the polymer component comprises one or more cellulose ethers and/or one or more acrylates, and wherein the pharmaceutical dosage form provides controlled release of the Tapentadol component. | 2018-12-27 |
20180369152 | RAPIDLY DISINTEGRATING GELATINOUS COATED TABLETS - The present invention relates to an improved gelatinous coated dosage form having two end regions coated with gelatinous materials and an exposed circumferential band. Openings are provided in at least the exposed band to reveal the core material. The invention also relates to methods for manufacturing such gelatinous coated dosage forms. | 2018-12-27 |
20180369153 | SOLID ORAL DOSAGE FORM OF IRINOTECAN FOR THE TREATMENT OF CANCER - Provided is a composition, in particular a solid pharmaceutical composition comprising a compound having the formula I | 2018-12-27 |
20180369154 | ACID-RESISTANT CAPSULE - An acid-resistant capsule includes a shell body, a cap, and a coating layer; wherein the shell body and the cap are telescopically engaged together and the coating layer coated on the shell body is between the shell body and the cap. The shell body has a compartment and a first open end, the compartment is inside the shell body, and the first open end communicates with the compartment. | 2018-12-27 |
20180369155 | METHOD FOR THE PREPARATION OF PARTICLES WITH CONTROLLED SHAPE AND/OR SIZE - A method for preparation of liquid, semi-liquid or solid particles through formation of an initial emulsion and consecutive deformation and/or breakage of the particles by means of temperature change. The formed particles may further be polymerized, physically or chemically modified and/or functionalized. The shape and size of the particles depend on the oil used, the size of the emulsion droplets in the initial emulsion, the surfactant used and the cooling/heating rate or temperature, and finally the nature of the additives. The method allows the preparation of a diverse range of particle shapes: rod-like, with different aspect ratios (1a, 1b); triangular (1c); triangular with inscribed geometrical shapes (d); deformed and/or elongated triangular shapes (e, f); quadrilateral shapes (g, h); quadrilateral shapes with inscribed geometrical shapes (i); hexagonal (j); hexagonal with inscribed geometrical shapes (k, l); and/or polygonal shape (m). | 2018-12-27 |
20180369156 | FORMULATIONS FOR ORAL DELIVERY OF ADSORBENTS IN THE GUT - The invention relates to a formulation for the delayed and controlled delivery of an adsorbent into the lower intestine of mammals. The formulation includes a carrageenan and an adsorbent, such as activated charcoal. The invention further relates to uses of this formulation, in particular to pharmaceutical uses. In one embodiment, the formulation is used to eliminate or reduce the side effects in the intestine, in particular in the colon, of pharmaceutical agents that are administered as a treatment for a disorder, but that have side effects when they reach the late ileum, the caecum or the colon. | 2018-12-27 |
20180369157 | Multiparticulate L-Carnitine Compositions and Related Methods - An oral controlled-release multiparticulate dosage form comprises a plurality of individually enteric coated particulates containing an L-carnitine that independently disperse in a patient's stomach after oral ingestion and travel through the stomach and past the pyloric sphincter without substantially releasing the L-carnitine in the stomach. The individual particulates contain (a) a solid core containing the L-carnitine, (b) a subcoating containing a cellulosic water soluble polymer over the core, and (c) an enteric coating over the subcoating. The dosage form may be used to treat conditions associated with a reduction of the amount of L-carnitine in the body. | 2018-12-27 |
20180369158 | NUCLEIC ACID NANOCAPSULES FOR DRUG DELIVERY AND TARGETED GENE KNOCKDOWN - The present disclosure provides multifunctional nanoparticles. More particularly, the present disclosure relates to multifunctional nanoparticles having one or more of nucleic acid ligands; and methods of using such nanoparticles for treatment and/or diagnosis of diseases and conditions. | 2018-12-27 |
20180369159 | PROTEIN NANOCAPSULES WITH DETACHABLE ZWITTERIONIC COATING FOR PROTEIN DELIVERY - The invention relates to protein nanocapsules that exhibit material properties that change in different in vivo environments. A zwitterion moiety on the surface of the nanocapsule can protect the protein from opsonization in a first environment, yet uncouples from the protein nanocapsule in a second environment (e.g. at a pH of less than 6.5). In embodiments of the invention, the uncoupled protein nanocarrier is then internalized by mammalian cells (e.g. tumor cells). | 2018-12-27 |
20180369160 | DEVICES AND METHODS FOR LOCAL DELIVERY OF TACROLIMUS OR DERIVATIVES THEREOF - Devices for local delivery of tacrolimus or a derivative thereof are provided, wherein the devices comprise a polymeric matrix containing tacrolimus or a derivative thereof that provides for delayed and extended release of tacrolimus or a derivative thereof. The devices can locally deliver tacrolimus or a derivative thereof to injured nervous system tissue upon implantation in a subject. Thus, techniques for local delivery of tacrolimus or a derivative thereof and methods of treatment using such devices are also provided. | 2018-12-27 |
20180369161 | NALFURAFINE-CONTAINING PERCUTANEOUS ABSORPTION PATCH - The present invention relates to a nalfurafine-containing percutaneous absorption patch having a support, a drug layer and a control layer which are laminated successively, wherein the drug layer contains at least one kind of a drug selected from the group consisting of nalfurafine and a salt thereof, and capable of maintaining a given level of drug skin permeation amount without permeation of an excess amount of the drug through the skin in a short time even when applied to the skin in which the horny cell layer and the like are damaged and the skin barrier is insufficient. | 2018-12-27 |
20180369162 | NOVEL USE OF PINOCARVEOL - The present invention relates to a pharmaceutical composition comprising pinocarveol for preventing or treating metabolic diseases, and functional food composition using the pharmaceutical composition for improving or alleviating metabolic diseases. Pinocarveol according to the present invention reduces weight, visceral fat, and cholesterol concentration, improves blood liver function index, reduces blood sugar, and additionally inhibits a metabolic inflammation reaction, and thus can be effectively used ultimately as a medical or functional food composition exhibiting prevention or treatment activities for metabolic diseases selected from the group consisting of obesity, diabetes, dyslipidemia, and syndromes of fatty liver and insulin-resistance. | 2018-12-27 |
20180369163 | ANTIBACTERIAL S-HETEROSUBSTITUTED DISULFIDES - Synthetically-derived S,S-heterodisubstituted disulfides that exhibit potent in vitro antibacterial activity against a variety of bacteria, including | 2018-12-27 |
20180369164 | USE OF COENZYME Q10 FORMULATIONS IN THE TREATMENT AND PREVENTION OF EPIDERMOLYSIS BULLOSA - The present invention is directed, in part, to methods of treating Epidermolysis Bullosa (EB) in a subject in need thereof, comprising topical administration of a pharmaceutical composition comprising a therapeutically effective amount of a of Coenzyme Q10 (CoQ10) to the subject. | 2018-12-27 |
20180369165 | Deacetylnemorone Abietane Diterpenoids for Use in Cancer Treatment - A deacetylnemorone abietane diterpenoid is utilized in the prevention of growth and development of pathogenic cells, e.g., cancer cells. The deacetylnemorone can have the following structure: | 2018-12-27 |
20180369166 | GARCINOL COMPOSITIONS FOR THERAPEUTIC MANAGEMENT OF ENDOPLASMIC RETICULUM STRESS - Disclosed is the use of garcinol for the therapeutic management of ER stress. More specifically, the invention discloses the ability of garcinol in decreasing ER stress and mitigating toxicity by reducing protein aggregation and decreasing expression of ER stress markers SXBP, GRP78 and ATF4, which indicates translational attenuation and recovery in hyperglycemia, paracetamol, alcohol, thapsigargin and high fat diet induced toxicity models. | 2018-12-27 |
20180369167 | METHODS FOR TREATING CANCER - The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity. | 2018-12-27 |
20180369168 | METHOD FOR TREATING HYPERHIDROSIS - The present invention relates to dexmecamylamine and the use of dexmecamylamine, substantially free of exo-R-mecamylamine, in the treatment of hyperhidrosis. | 2018-12-27 |
20180369169 | SPHINGOSINE PATHWAY MODULATING COMPOUNDS FOR THE TREATMENT OF CANCERS - The invention provides methods and compositions for treating cancers and myeloproliferative disorders using sphingosine kinase-1 inhibitors, such as SK1-I, and selective sphingosine-1-phosphate receptor agonists, such as ozanimod. | 2018-12-27 |
20180369170 | METHOD OF TREATMENT WITH ANTI-INFLAMMATORY AND ANALGESIC COMPOUNDS WHICH ARE GI-, RENAL-, AND PLATELET-SPARING - Disclosed herein are compounds, pharmaceutical compositions, and methods for the treatment of diseases such as inflammation and/or pain, comprising the administration of a therapeutically effective amount of a non-steroidal, non-opioid compound having GI-/renal-/platelet-sparing activities, and wide safety margins with no appreciable inhibition of either form of cyclooxygenase. | 2018-12-27 |
20180369171 | PPAR-ALPHA AGONIST TREATMENT OF NEUROPSYCHIATRIC DISORDERS - Described herein are PPARα agonists, including, but not limited to, endocannabinoids that can be used for treatment of a neuropsychiatric disorder and/or symptom thereof. Also described herein are pharmactiutical formulations containing an effective amount of a PPARα agonists, including but not limited to endocannabinoids, where the effective amount is effective for treating a neuropsychiatric disorder and/or symptom thereof. Also described herein are methods of treating a neuropsychiatric disorder and/or a symptom thereof in a subject in ned thereof. | 2018-12-27 |
20180369172 | METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING WITH DECREASED SCAR FORMATION AFTER GLAUCOMA FILTRATION SURGERY - Disclosed is a method of promoting wound healing with reduced scarring after glaucoma filtration surgery in a mammalian subject in need thereof, which involve the use of a HDAC inhibitor (HDACi), such as, but not limited to, suberoylanilide hydroxamic acid (SAHA). | 2018-12-27 |
20180369173 | Increasing Cancer Patient Survival Time by Administration of Dithio-Containing Compounds - The present invention discloses and claims compositions, methods of treatment, and kits which cause an increase in the time of survival in cancer patients, wherein the cancer: (i) overexpresses thioredoxin or glutaredoxin and/or (ii) exhibits evidence of thioredoxin- or glutaredoxin-mediated resistance to one or more chemotherapeutic interventions. The present invention also discloses and claims methods and kits for the administration of said compositions to properly treat cancer patients. Additionally, the present invention discloses and claims methods and kits for quantitatively determining the level of expression of thioredoxin or glutaredoxin in the cancer cells of a cancer patient, methods of using those determined levels in the initial diagnosis and/or planning of subsequent treatment methodologies for said cancer patient, as well as ascertaining the potential growth “aggressiveness” of the particular cancer and treatment responsiveness of the particular type of cancer. Further, the present invention discloses and claims novel pharmaceutical compositions, methods, and kits used for the treatment of patients with medical conditions and disease where there is the overexpression of thioredoxin and/or glutaredoxin, and wherein this overexpression is associated with deleterious physiological effects in the patients. | 2018-12-27 |
20180369174 | METHODS AND COMPOSITIONS FOR TREATING PERIPHERAL NEUROPATHY - The present disclosure provides methods and compositions which treat, alleviate, prevent, diminish or otherwise ameliorate the symptoms associated with peripheral neuropathies (e.g., neuropathic pain) or sunburn in a subject. Specifically, the present invention relates to topically administering a therapeutically effective amount of a pharmaceutically safe therapeutic agent directly to the region exhibiting pain in a subject. | 2018-12-27 |
20180369175 | NUTRITIONAL SUPPLEMENT AND USE TO PREVENT NUTRITIONAL DEFICIENCIES IN PATIENTS UNDERGOING TREATMENT IN WHICH PROTON PUMP INHIBITORS ARE ADMINISTERED - A formulation and method for treating or preventing a deficiency of certain nutrients in patients undergoing a therapy in which one or more proton pump inhibitors is administered. The formulation includes:
| 2018-12-27 |
20180369176 | WOUND CLEANSING METHOD - An aqueous composition with a higher-than-neutral pH includes a significant amount of one or more surfactants and large amounts of osmotically active solutes. This composition, as well as an acidic counterpart and solid materials, can be used in a variety of applications such as wound care, oral care, medical equipment reprocessing, healthcare acquired infection and implant treatment. | 2018-12-27 |
20180369177 | COMPOSITIONS AND METHODS FOR INDUCING SATIETY AND TREATING NON-INSULIN DEPENDENT DIABETES MELLITUS, PRE-DIABETIC SYMPTOMS, INSULIN RESISTANCE AND RELATED DISEASE STATES AND CONDITIONS - The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release dosage form, wherein the dosage form is administered while the subject is in the fasted state and at a time of around six to around nine hours prior to the subject's next intended meal, and wherein the dosage form comprises a controlled release composition, which comprises an enterically-coated, ileum hormone-stimulating amount of a nutritional substance and releases the majority of the nutritional substance in vivo upon reaching the subject's ileum. The invention also provides a diagnostic tool for probing the health and disease state of the ileal hormones, excess or deficiencies. The invention provides a safe vehicle for targeted deliveries of chemical, pharmaceuticals, natural substances and nutrition to the ileum. The present invention also provides a method for treating noninsulin dependent diabetes mellitus, pre-diabetic symptoms, and insulin resistance, as well as a number of disease states and conditions including gastrointestinal disorders as otherwise described herein. | 2018-12-27 |
20180369178 | Methods of Treating Hair Related Conditions - Disclosed herein are methods for treating hair related disorders, including compounds that may be specific or modulate PPAR receptors. | 2018-12-27 |
20180369179 | METHODS OF TREATING OR PREVENTING FIBROTIC LUNG DISEASES - The invention includes a method of preventing or treating a fibrotic lung disease in a subject, comprising administering to the subject a thyroid hormone by inhalation and/or aerosolization. The invention further comprises compositions and kits comprising compositions useful within the invention. | 2018-12-27 |
20180369180 | DOSAGE FORMS AND THERAPEUTIC USES OF L-4-CHLOROKYNURENINE - Compositions of L-4-chlorokynurenine are provided, as are methods for the treatment of neurological dysfunction | 2018-12-27 |
20180369181 | TREATMENT OF NERVOUS SYSTEM DISORDERS USING COMBINATIONS OF RXR AGONISTS AND THYROID HORMONES - Disclosed herein are methods of treating disease with a combination of a RXR agonist and a thyroid hormone. | 2018-12-27 |
20180369182 | TOPICAL PHARMACEUTICAL COMPOSITION OF ACITRETIN - The present invention relates to a topical pharmaceutical composition comprising acitretin and a process for its preparation. It also relates to a method of treating skin disorders by administering said topical pharmaceutical composition. | 2018-12-27 |
20180369183 | PHARMACEUTICAL COMPOSITIONS OF DIMETHYL FUMARATE - The present invention relates to pharmaceutical compositions comprising dimethyl fumarate and a pharmaceutically acceptable agent which inhibits the enzyme catalyzed degradation of dimethyl fumarate. | 2018-12-27 |
20180369184 | Compositions and Uses and Methods Relating Thereto - A method for delivering a benefit agent to the surface of the eye, the method comprising applying an ocular benefit composition to a lid margin of the eye wherein the ocular benefit composition comprises at least 5 wt % of one or more lipid and/or lipid derived compounds. | 2018-12-27 |
20180369185 | SELF-EMULSIFYING COMPOSITION OF w3 FATTY ACID - This invention provides a self-emulsifying composition comprising 50 to 95% by weight in total of at least one compound selected from the group consisting of ω3 polyunsaturated fatty acids and their pharmaceutically acceptable salts and esters; and 5 to 50% by weight of an emulsifier having a hydrophilic lipophilic balance of at least 10. The composition has no or reduced ethanol content, and exhibits excellent self-emulsifying property, dispersibility in the composition, emulsion stability, and absorption property. The composition is adapted for use as a drug. | 2018-12-27 |
20180369186 | METHOD FOR MODULATING AUTOPHAGY AND APPLICATIONS THEREOF - The present disclosure relates to method of modulating autophagy by modulators of autophagy, wherein the autophagy includes but is not limited to macroautophagy, chaperone mediated autophagy and microautophagy. The present disclosure further relates to modulators of autophagy for increasing or decreasing the autophagic flux. The disclosure also relates to modulator per se in modulating autophagy including but not limiting to macroautophagy, chaperon mediated autophagy and microautophagy. | 2018-12-27 |
20180369187 | TREATMENT OF ALLERGIC RHINITIS USING A COMBINATION OF MOMETASONE AND OLOPATADINE - The present invention relates to a method of treating allergic rhinitis in a subject (e.g., a human) in need thereof comprising nasally administering to the subject an effective amount of a fixed-dose pharmaceutical composition comprising mometasone or its salt and olopatadine or its salt. | 2018-12-27 |
20180369188 | APPLICATION OF PHOSPHODIESTERASE 4 INHIBITOR ZL-N-91 IN PREPARATION OF MEDICATIONS FOR LUNG CANCER PROLIFERATION AND METASTASIS - The present invention discloses uses of a novel phosphodiesterase 4 (PDE4) inhibitor ZL-n-91 in preparing drugs against lung cancer proliferation and metastasis. The mouse survival curves and in vitro cell experiments show that the PDE4 inhibitor ZL-n-91 can significantly inhibit the proliferation and metastasis of lung cancer cells, indicating that this PDE4 inhibitor ZL-n-91 can become an important target for the studies on anti-lung cancer proliferation and metastasis, to provide a basis for preparing drugs against lung cancer proliferation and metastasis, with promising prospect of development and application. | 2018-12-27 |
20180369189 | CANCER SPECIFIC LIPID TARGETED PEPTIDOMEMETICS - A phosphatidylserine targeted peptoid has been identified with the ability to bind to cancer cells globally and specifically. A dimer of the peptoid decreases cancer cell viability. Use of the dimerized peptoid enhances the efficacy of docetaxel. The peptoid can be used for including but not limited to diagnosing and treating cancer, diagnosing and treating a viral condition, and diagnosing and treating diabetes. | 2018-12-27 |
20180369190 | COMPOUNDS FOR TARGETING THYROID HORMONE RECEPTOR ALPHA ISOFORMS AND METHODS OF USE THEREOF - Two isoforms of thyroid receptor alpha (THRα1 and THRα2) have been found to be associated with the growth of cancer. Use of inhibitors of THRα1 (Formula I) and/or agonists of THRα2 (Formula II) in the treatment of such cancers is disclosed. Treatment of other disorders associated with such receptors is also contemplated, as is the use of diagnostic methods for predicting therapeutic outcomes based on the levels of expression of THRα1 and THRaα2 in a tissue sample. | 2018-12-27 |
20180369191 | BLENDED CANNABIS COMPOUNDS AND METHODS OF MAKING THE SAME - Blended, processed marijuana and/or hemp | 2018-12-27 |
20180369192 | TERPENE-BASED COMPOSITIONS, METHODS OF PREPARATIONS AND USES THEREOF - The present disclosure generally relates to terpene-based compositions for applications in the pharmaceutical and recreational fields. In some embodiments, the compositions are enriched compositions or non-naturally occurring compositions which contain defined concentrations of one or more | 2018-12-27 |
20180369193 | AVOCADO FLESH AND/OR SKIN EXTRACT RICH IN POLYPHENOLS AND COSMETIC, DERMATOLOGICAL AND NUTRACEUTICAL COMPOSITIONS COMPRISING SAME - The invention relates to an avocado extract rich in polyphenols, containing at least 10% by weight of polyphenols, expressed in gallic acid equivalent relative to the dry extract obtained, wherein said polyphenols contain procyanidins, cafeic acid and cafeic acid derivatives, typically in a proportion of at least 70% by weight, expressed in gallic acid equivalent relative to the total polyphenol content by weight. The invention also relates to a composition comprising an extract according to the invention as active agent and a suitable excipient. The invention also relates to such a composition or such an extract for use thereof in preventing or treating disorders or pathological conditions of the skin, the mucous membranes or the superficial body growths. Finally, the invention relates to a cosmetic care process for the skin, the superficial body growths or the mucous membranes, with a view to improving the condition thereof or the appearance thereof, which consists in administering such a composition or such an extract. | 2018-12-27 |
20180369194 | TABLET COMPRISING 1-(3-(2-(1-BENZOTHIOPHEN-5-YL)ETHOXY)PROPYL)AZETIDIN-3-OL OR SALT THEREOF - A tablet which comprises (1) 1-(3-(2-(1-benzothiophen-5- yl)ethoxy)propyl)azetidin-3-ol or a salt thereof and (2) ethyl cellulose, said tablet having excellent elution properties and good moldability, remaining stable during prolonged storage, and exhibiting high impact resistance. | 2018-12-27 |
20180369195 | COMBINATION THERAPY FOR TREATMENT OF MELANOMA - The present disclosure provides a pharmaceutical composition that inhibits the proliferation of a cancer cell, comprising a first compound selected from indole-3-carbinol (I3C), 1-benzyl I3C, or a pharmaceutically acceptable salt or ester thereof, and a second compound that binds to and inhibits: i) an oncogenic RAF polypeptide at a site that is distinct from the site at which the first compound binds; ii) a polypeptide of the RAF signaling pathway; iii) a polypeptide of the Wnt-β-catenin signaling pathway; iv) or a polypeptide of the PI3K/AKT/mTOR signaling pathway. The present disclosure also provides a method of treating cancer in a subject. | 2018-12-27 |
20180369196 | PPARG Modulators for the Treatment of Osteoporosis - The invention provides methods of treatment of a progressive bone disease, such as osteoporosis, Paget's Disease, multiple myeloma, or hyperparathyroidism, comprising administration of an effective amount of a non-agonist PPARG modulator to a patient afflicted with the disease. | 2018-12-27 |
20180369197 | METHODS AND COMPOSITIONS ASSOCIATED WITH THE GRANULOCYTE COLONY-STIMULATING FACTOR RECEPTOR - Some embodiments include compositions and methods of using or identifying compounds that modulate the activity of the granulocyte colony-stimulating factor receptor (GCFR). Some embodiments include use of compounds to treat certain disorders, such as hematopoietic or neurological disorders. | 2018-12-27 |
20180369198 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OBESITY - The present invention relates to methods and pharmaceutical compositions for the treatment of obesity. In particular, the present invention relates to a method of treating obesity in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an indoleamine 2-3 dioxygenase (IDO) inhibitor. | 2018-12-27 |
20180369199 | TITRATION OF CEBRANOPADOL - The invention relates to Cebranopadol for use in the treatment of pain, wherein Cebranopadol is administered according to an administration regimen comprising
| 2018-12-27 |
20180369200 | COMPOUNDS FOR THE TREATMENT OF CANCERS ASSOCIATED WITH HUMAN PAPILLOMAVIRUS - The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus. | 2018-12-27 |
20180369201 | DBH INHIBITORS FOR TREATING OR PREVENTING MEMORY LOSS - The present invention relates to the use of DBH inhibitors (e.g., disulfiram and Nepicastat), and pharmaceutical compositions thereof, for treating subjects with certain types of memory loss, for instance memory loss associated with a neurodegenerative disease, disorder, or condition, such as Alzheimer's Disease. | 2018-12-27 |
20180369202 | CHK1/2 Inhibitors for Use in the Treatment of Neuroblastomas and/or Soft Tissue Sarcomas - The present invention provides 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine˜2˜carbonitrile and pharmaceutically acceptable salts and solvates thereof that is capable of inhibiting CHK1 and is useful in the treatment of neuroblastomas and/or soft tissue sarcomas. | 2018-12-27 |
20180369203 | METHODS OF TREATING CANCER BY ADMINISTERING A MEK INHIBITOR IN COMBINATION WITH A PROTEASOME INHIBITOR - Presently disclosed are methods of treating cancer comprising administering a MEK inhibitor in combination with a proteasome inhibitor. In some embodiment, the cancer is a solid tumor. In some instances, the cancer has at least one mutation chosen from a NF1, RAS (including N-, K-, and H-RAS), RAF (including A-, B-, and C-RAF), and MEK (including MEK1 and MEK2) mutation. In some embodiments, the cancer is resistant to treatment with at least one of a proteasome inhibitor or a MEK inhibitor. In some embodiments, the combination therapy produces a synergistic effect. | 2018-12-27 |
20180369204 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER - The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: | 2018-12-27 |
20180369205 | Heterobifunctional Pan-Selectin Antagonists Having a Triazole Linker - Compounds, compositions, and methods for modulating in vitro and in vivo processes mediated by selectin binding. For example, heterobifunctional compounds that inhibit both E-selectins and P-selectins are described, wherein the selectin modulators that modulate (e.g., inhibit or enhance) a selectin-mediated function comprise particular glycomimetics linked to a member of a class of compounds termed BASAs (Benzyl Amino Sulfonic Acids). The compounds are of formula (Ia) wherein the substituents are as defined in the claims. | 2018-12-27 |
20180369206 | Methods of Use for Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors - The present invention provides methods for treating a cancer in a subject and for inhibiting tumor growth, metastasis or a dihydrorotate oxygenase enzyme activity of a tumor or cancer cell. At least one trisubstituted benzotriazole derivative with the formula (I) | 2018-12-27 |